Wednesday, September 14, 2016

Betamethasone Dipropionate topical



Class: Anti-inflammatory Agents
Note: This monograph also contains information on Betamethasone, Betamethasone Valerate
ATC Class: D07BC01
VA Class: DE200
CAS Number: 378-44-9
Brands: Alphatrex, Betatrex, Beta-Val, Diprolene, Lotrisone, Luxiq, Maxivate, Taclonex

Introduction

A synthetic fluorinated corticosteroid.101 102 103 104 105 106 108 112 113 114 115 116 117 b


Uses for Betamethasone Dipropionate


Corticosteroid-responsive Dermatoses


Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.101 102 104 106 105 107 108 109 110 111 112 113 114


Generally most effective in acute or chronic dermatoses (e.g., seborrheic or atopic dermatitis, localized neurodermatitis, anogenital pruritus, psoriasis, late phase of allergic contact dermatitis, inflammatory phase of xerosis).e


Topical therapy generally preferred over systemic therapy; fewer associated adverse systemic effects.e


Topical therapy generally only controls manifestations of dermatoses; eliminate cause if possible.e


Topical efficacy may be increased by using a higher concentration or occlusive dressing therapy.e (See Administration with Occlusive Dressing under Dosage and Administration.)


Response may vary from one topical corticosteroid preparation to another.e


Anti-inflammatory activity may vary considerably depending on the vehicle, drug concentration, site of application, disease, and individual patient.e


Cream and lotion (0.05% betamethasone dipropionate; 0.1% betamethasone valerate) are considered to have medium-range potency.101 103


Foam (0.12% betamethasone valerate) is considered to have medium-range potency.108


Ointment (0.05% betamethasone dipropionate) is considered to have high-range potency.102


Cream, lotion, and ointment (0.05% betamethasone dipropionate) in optimized (augmented) vehicle are considered to have high-range potency.104 106 b


Fixed-combination cream or lotion containing betamethasone dipropionate 0.05% and clotrimazole 1% is considered to have high-range potency.115


Gel (0.05% betamethasone dipropionate) in optimized (augmented) vehicle is considered to have super-high range potency.104


Inflammatory Tinea Pedis, Tinea Cruris, or Tinea Corporis


Used in fixed combination with clotrimazole in the treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis caused by Epidermophyton floccosum, Trichophyton rubrum, and T. mentagrophytes.115


Safety and efficacy of topical betamethasone preparations in fixed combination with clotrimazole for the treatment of infections caused by zoophilic dermatophytes (e.g., Microsporum canis) have not been established.115


Treatment failure of topical betamethasone preparations in fixed combination with clotrimazole in the treatment of M. canis infections has been reported.115


Psoriasis


Used in fixed combination with calcipotriene for the topical treatment of plaque psoriasis (psoriasis vulgaris) in adults.116


Used in fixed combination with calcipotriene for the topical treatment of chronic, moderate to severe plaque psoriasis (psoriasis vulgaris) of the scalp in adults.117


Betamethasone Dipropionate Dosage and Administration


General



  • Consider location of the lesion and the condition being treated when choosing a dosage form.e




  • Creams are suitable for most dermatoses, but ointments may also provide some occlusion and are usually used for the treatment of dry, scaly lesions.e




  • Lotions are probably best for treatment of weeping eruptions, especially in areas subject to chafing (e.g., axilla, foot, groin).e Lotions, gels, and aerosols may be used on hairy areas, particularly the scalp.e




  • Formulation affects percutaneous penetration and subsequent activity; extemporaneous preparation or dilution of commercially available products with another vehicle may decrease effectiveness.e




  • Patients applying a topical corticosteroid to a large surface area and/or to areas under occlusion should be evaluated periodically for evidence of hypothalamic-pituitary-adrenal (HPA)-axis suppression by appropriate endocrine testing (e.g., ACTH stimulation, plasma cortisol, urinary free cortisol).101 102 103 104 105 106 b (See Hypothalamic-Pituitary-Adrenal Axis Suppression and also see Systemic Effects, under Cautions.)



Administration


Topical Administration


For dermatologic use only; avoid contact with eyes.101 102 103 104 105 106 112 113 114 116 117 b


Betamethasone dipropionate gel in optimized (augmented) vehicle and fixed-combination ointment or suspension containing betamethasone dipropionate and calcipotriene should not be used on the face, groin, or in the axillae.105 116 117


Cream or lotion containing betamethasone dipropionate in fixed combination with clotrimazole or, alternatively, ointment or suspension containing betamethasone dipropionate in fixed combination with calcipotriene is not intended for ophthalmic, oral, or intravaginal use.115 116 117


The area of skin to be treated may be thoroughly cleansed before topical application to reduce the risk of infection; however, some clinicians believe that, unless an occlusive dressing is used, cleansing of the treated area is unnecessary and may be irritating.e


Apply cream or ointment in a thin film to the affected area.101 102 104 112 113 b


Apply gel in a thin film and rub gently into affected area until absorbed.105


Apply betamethasone dipropionate and calcipotriene fixed-combination ointment and rub gently and completely into affected area.116 Wash hands thoroughly after application process.116


Apply foam to affected areas of the scalp.108 To dispense foam, invert container; dispense small amount of foam onto a cool surface (e.g., saucer) to prevent melting.108 Foam will melt immediately upon contact with warm skin; do not dispense directly onto hands.108 Gently massage foam into the entire affected area of scalp.108


Apply betamethasone dipropionate and calcipotriene fixed-combination suspension to affected areas of the scalp.117 Wash hands thoroughly after application process.117 Shake fixed-combination suspension well before each use.117


Apply a few drops of lotion to the affected area by holding the nozzle of the bottle close to the affected area and squeezing gently; massage lightly until absorbed.103 106 114


Shake lotion containing betamethasone valerate and lotion containing betamethasone dipropionate in fixed combination with clotrimazole well before each use.114 115


After a favorable response is achieved, frequency of application may be decreased to the minimum necessary to maintain control and to avoid relapse; discontinue if possible.d


Administration with Occlusive Dressing

Topical preparations of betamethasone dipropionate alone or in fixed combination with clotrimazole or calcipotriene should not be used with occlusive dressings.101 102 103 104 105 115 116 117 b However, when appropriate, occlusive dressings may be used as directed by a clinician to augment efficacy of betamethasone valerate preparations when treating resistant dermatoses.108 112 113 114 (See Occlusive Dressings under Cautions.)


Soak or wash the affected area to remove scales; apply a thin film of cream, lotion, or ointment; rub gently into the lesion; and apply another thin film.e Cover affected area with a thin, pliable plastic film and seal it to adjacent normal skin with adhesive tape or hold in place with a gauze or elastic bandage.e


If affected area is moist, incompletely seal the edges of the plastic film or puncture the film to allow excess moisture to escape.e For added moisture in dry lesions, apply cream, ointment, or lotion and cover with a dampened cloth before the plastic film is applied or briefly soak the affected area in water before application of the drug and plastic film.e


Thin polyethylene gloves may be used on the hands and fingers, plastic garment bags may be used on the trunk or buttocks, a tight shower cap may be used for the scalp, or whole-body suits may be used instead of plastic film to provide occlusion.e


The frequency of occlusive dressing changes depends on the condition being treated; cleansing of the skin and reapplication of the corticosteroid are essential at each dressing change.e


Occlusive dressing usually is left in place for 12–24 hours and therapy is repeated as needed.e Although occlusive dressing may be left in place for 3–4 days at a time in resistant conditions, most clinicians recommend intermittent use of occlusive dressings for 12 hours daily to reduce the risk of adverse effects (particularly infection) and systemic absorption and for greater convenience.e


The drug and an occlusive dressing may be used at night, and the drug or a bland emollient may be used without an occlusive dressing during the day.e


In patients with extensive lesions, sequential occlusion of only one portion of the body at a time may be preferable to whole-body occlusion.e (See Occlusive Dressings under Cautions.)


Dosage


Available as betamethasone dipropionate and betamethasone valerate; dosage usually expressed in terms of betamethasone.101 102 103 104 105 112 113 114 115 116 117 b


Foam available as betamethasone valerate; dosage expressed in terms of betamethasone valerate.108


Pediatric Patients


Administer the least amount of topical preparations that provides effective therapy.101 (See Pediatric Use under Cautions.)


Corticosteroid-responsive Dermatoses

Topical (Betamethasone Dipropionate)

Children ≥13 years of age: Apply 0.05% cream in a thin film to affected area, usually once daily or, if necessary, twice daily.101


Children ≥13 years of age: Apply 0.05% cream in optimized (augmented) vehicle or 0.05% ointment in a thin film to affected area once or twice daily.102 104 b


Children ≥13 years of age: Apply a few drops of 0.05% lotion to affected area once or twice daily.103


Children ≥12 years of age: Apply 0.05% gel in optimized (augmented) vehicle or 0.05% ointment in optimized (augmented) vehicle in a thin film to affected area once or twice daily.105


Children ≥12 years of age: Apply a few drops of 0.05% lotion in optimized (augmented) vehicle to affected area once or twice daily.106


Topical (Betamethasone Valerate)

Apply 0.1% cream or ointment to affected area 1–3 times daily; once- or twice-daily application often is effective.112 113


Apply a few drops of 0.1% lotion to affected area twice daily, in the morning and evening.114 Dosage may be increased in patients with resistant dermatoses; decrease frequency to once daily following clinical improvement.114


Adults


Corticosteroid-responsive Dermatoses

Topical (Betamethasone Dipropionate)

Apply 0.05% cream in a thin film to affected area, usually once daily or, if necessary, twice daily.101


Apply 0.05% cream in optimized (augmented) vehicle, 0.05% gel in optimized (augmented) vehicle, 0.05% ointment or ointment in optimized (augmented) vehicle in a thin film to affected area once or twice daily.102 104 105 b


Apply a few drops of 0.05% lotion or 0.05% lotion in optimized (augmented) vehicle to affected area once or twice daily.103 106 ”


Topical (Betamethasone Valerate)

Apply 0.1% cream or ointment to affected area 1–3 times daily; once- or twice-daily application is often effective.112 113


Apply 0.12% foam twice daily in the morning and evening.108 Discontinue when control is achieved; if response is inadequate within a 2-week course of therapy, consider reevaluation of diagnosis.108


Apply a few drops of 0.1% lotion to affected area twice daily, in the morning and evening.114 Dosage may be increased in patients with resistant dermatoses; decrease frequency to once daily following clinical improvement.114


Symptomatic Inflammatory Tinea Pedis, Tinea Cruris, or Tinea Corporis

Topical (Betamethasone Dipropionate and Clotrimazole)

Apply cream or lotion containing betamethasone 0.05% and clotrimazole 1% twice daily in the morning and evening.115


If response is inadequate within a 1-week (tinea corporis or tinea cruris) or 2-week (tinea pedis) course of therapy with the combination of betamethasone 0.05% and clotrimazole 1%, reevaluate diagnosis or discontinue combination preparation and consider clotrimazole alone.115 f


Plaque Psoriasis

Topical (Betamethasone Dipropionate and Calcipotriene)

Apply ointment containing betamethasone 0.05% and calcipotriene 0.005% to the affected area(s) once daily.116


Apply suspension containing betamethasone 0.05% and calcipotriene 0.005% to affected area(s) of the scalp once daily for 2 weeks or until cleared.117


Prescribing Limits


Pediatric Patients


Corticosteroid-responsive Dermatoses

Topical (Betamethasone Dipropionate)

Maximum 45 g weekly with 0.05% cream in optimized (augmented) vehicle or with 0.05% ointment in optimized (augmented) vehicle.104


Maximum 50 g weekly with 0.05% gel in optimized (augmented) vehicle or 50 mL weekly with 0.05% lotion in optimized (augmented) vehicle; do not exceed 2 consecutive weeks of therapy.105


Adults


Corticosteroid-responsive Dermatoses

Topical (Betamethasone Dipropionate)

Maximum 45 g weekly with 0.05% cream in optimized (augmented) vehicle or with 0.05% ointment in optimized (augmented) vehicle.104


Maximum 50 g weekly with 0.05% gel in optimized (augmented) vehicle or 50 mL weekly with 0.05% lotion in optimized (augmented) vehicle; do not exceed 2 consecutive weeks of therapy.105


Symptomatic Inflammatory Tinea Pedis, Tinea Cruris, or Tinea Corporis

Topical (Betamethasone Dipropionate and Clotrimazole)

Maximum 45 g (cream) or 45 mL (lotion) weekly of the fixed combination of betamethasone 0.05% and clotrimazole 1%; do not exceed 2 consecutive weeks of therapy in the treatment of tinea cruris or tinea corporis or 4 weeks in the treatment of tinea pedis.115


Plaque Psoriasis

Topical (Betamethasone Dipropionate and Calcipotriene)

Maximum 100 g weekly of the fixed-combination betamethasone 0.05% and calcipotriene 0.005% ointment.116 Do not apply to >30% of body surface area.116 Do not exceed 4 consecutive weeks of therapy.116


Maximum 100 g weekly of the fixed-combination betamethasone 0.05% and calcipotriene 0.005% suspension.117 Do not exceed 8 consecutive weeks of therapy.117


Cautions for Betamethasone Dipropionate


Contraindications



  • Known hypersensitivity to betamethasone dipropionate, betamethasone valerate, other corticosteroids, or any ingredient in the formulation.101 102 103 104 105 106 108 112 113 114 115 116 b




  • Betamethasone dipropionate and calcipotriene ointment or suspension: Known or suspected disorders of calcium metabolism.116 117




  • Betamethasone dipropionate and calcipotriene ointment or suspension: Erythrodermic, exfoliative, and pustular psoriasis.116 117



Warnings/Precautions


Sensitivity Reactions


Allergic contact dermatitis may manifest as failure to heal rather than irritation as occurs with other topical preparations that do not contain corticosteroids; confirm with diagnostic patch testing.105 116


Discontinue therapy with betamethasone dipropionate and calcipotriene fixed-combination ointment if irritation occurs.116


Major Toxicities


Risk of Systemic Effects with Highly Active Preparations

Betamethasone is a potent topical corticosteroid and can be absorbed in sufficient amounts to produce systemic effects including HPA axis suppression.102 103 104 105 106 112 113 114 116 117 b (See Hypothalamic-Pituitary-Adrenal Axis Suppression and also see Systemic Effects, under Cautions.)


General Precautions


Hypothalamic-Pituitary-Adrenal Axis Suppression

Topically applied corticosteroids can be absorbed in sufficient amounts to reversibly suppress the HPA axis.101 102 103 104 105 106 108 112 113 114 116 117 b e HPA-axis suppression has occurred following topical dosages as low as 7 g of the 0.05% betamethasone dipropionate cream in an optimized vehicle (3.5 mg of betamethasone) daily or following repeated application of 14 g of the 0.05% betamethasone dipropionate ointment in an optimized vehicle (7 mg of betamethasone) daily in patients with psoriasis.104 e


Perform periodic HPA-axis evaluation by appropriate testing (e.g., ACTH stimulation, morning plasma cortisol, urinary free cortisol), especially in patients applying a topical corticosteroid to a large surface area or to areas under occlusion.101 102 103 104 105 106 108 112 113 114 116 117 b e


If HPA-axis suppression occurs, withdraw the drug, reduce the frequency of application, discontinue occlusive therapy, and/or substitute a less potent corticosteroid.101 102 103 104 105 106 108 112 113 114 116 117 b e


HPA-axis function recovery generally is prompt and complete following drug discontinuance.101 102 103 104 105 106 108 112 113 114 116 117 b e


Rarely, glucocorticosteroid insufficiency may require systemic corticosteroid therapy.101 102 103 104 105 106 108 112 113 114 b e


Systemic Effects

Systemic absorption following topical administration may result in manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients.101 102 103 104 105 106 108 112 113 114 116 117 b e


Risk of adverse systemic effects increases with use of a high-potency topical corticosteroid, especially if applied to large areas of the body, for prolonged periods of time, with an occlusive dressing, and/or concurrently with other corticosteroid-containing preparations.101 102 103 104 105 106 108 112 113 114 116 117 b e


Infants and children may be more susceptible to adverse systemic effects.101 102 103 104 105 106 108 112 113 114 116 117 b e (See Pediatric Use under Cautions.)


Local Effects

Possible adverse local reactions (e.g., irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, striae, miliaria); may occur more frequently with the use of occlusive dressings, especially with prolonged therapy.108 113 114 115 116 117 e


Prolonged use of topical corticosteroids may cause atrophy of the epidermis and subcutaneous tissue;106 these effects are most likely to occur (even with short-term use) in intertriginous, flexor, and facial areas.106 Do not apply betamethasone and calcipotriene ointment or suspension to treatment areas with preexisting skin atrophy.116 117


If irritation occurs, discontinue drug and institute appropriate therapy.101 102 103 104 105 112 113 114 116


Skin Infection

If concurrent skin infection is present or develops, initiate appropriate anti-infective therapy.101 102 103 104 105 106 108 112 113 114 116 117 b If infection does not respond promptly, discontinue topical corticosteroid therapy until the infection has been controlled.101 102 103 104 105 106 108 112 113 114 116 117 b


When topical corticosteroids and topical anti-infectives are used concomitantly, consider that the corticosteroid may mask clinical signs of bacterial, fungal, or viral infections; prevent recognition of ineffectiveness of the anti-infective; or suppress hypersensitivity reactions to ingredients in the formulation.e h In addition, consider the cautions, precautions, and contraindications associated with the anti-infective.e h


Treatment of fungal infections with topical preparations containing betamethasone dipropionate in fixed combination with clotrimazole may lead to clinical worsening and/or decreased cure rate due to suppression of the inflammatory response.115


Fungal infections, especially noninflammatory tinea infections, may be treated effectively without the risk corticosteroid-associated adverse effects by using a topical antifungal agent that does not contain a corticosteroid.115


Do not use occlusive dressings in patients with primary skin infection.e


Some manufacturers state that topical corticosteroids are contraindicated in patients with tuberculosis of the skin, dermatologic fungal infections, and cutaneous or systemic viral infection, including vaccinia and varicella and herpes simplex of the eye or adjacent skin;d however, most clinicians believe topical corticosteroids can be used with caution if the infection is treated.d


Occlusive Dressings

Betamethasone dipropionate preparations should not be used with occlusive dressings.101 103 104 105 115 116 117 b


Betamethasone valerate preparations should not be used with occlusive dressings unless directed by clinician.108 112 113 114


Adverse systemic reactions may occur with use of occlusive dressings on large areas of the body and for prolonged periods of time; monitor accordingly.d (See Hypothalamic-Pituitary-Adrenal Axis Suppression and also see Systemic Effects, under Cautions.)


Adverse local reactions may occur more frequently with the use of occlusive dressings, especially with prolonged therapy.108 113 114 115 117 e (See Local Effects under Cautions.)


Do not use occlusive dressings on weeping or exudative lesions.e


Do not use occlusive dressings in patients with primary skin infection.e


Remove occlusive dressings covering large areas if body temperature increases; thermal homeostasis may be impaired.e


Use plastic occlusive material with care to avoid the risk of suffocation.e


Inadequate Response

If an adequate response is not achieved when treating tinea with topical preparations containing betamethasone dipropionate in fixed combination with clotrimazole, perform appropriate microbiologic studies (e.g., KOH smear and/or culture) to reconfirm the clinical diagnosis before instituting additional courses of therapy with combination preparation.115


Rosacea or Perioral Dermatitis

Betamethasone dipropionate gel in optimized (augmented) vehicle is not recommended for treatment of rosacea or perioral dermatitis.105


Use of Fixed Combinations

When used in fixed combination with calcipotriene or clotrimazole, consider the cautions, precautions, and contraindications associated with the concomitant agent.115 116 117


Specific Populations


Pregnancy

Category C.101 102 104 105 106 108 112 113 114 115 116 117 b


Lactation

Not known whether topical betamethasone is distributed into milk.101 102 103 104 105 108 112 113 114 115 116 117 b Caution advised if topical betamethasone is used.101 102 103 104 105 106 108 112 113 114 115 116 117 b


Pediatric Use

Use of betamethasone dipropionate cream, cream in optimized (augmented) vehicle, lotion, and ointment not recommended in children ≤12 years of age; these dermatologic preparations may be used with caution in children ≥13 years of age.101 103 104


Use of betamethasone dipropionate gel in optimized (augmented) vehicle, lotion in optimized (augmented) vehicle, and ointment in optimized (augmented) vehicle not recommended in children <12 years of age; these dermatologic preparations may be used with caution in children ≥12 years of age.105 106 b


Safety and efficacy of betamethasone valerate foam not established in pediatric patients.108


Use of preparations containing betamethasone dipropionate in fixed combination with clotrimazole are not recommended for use in the treatment of diaper dermatitis or for use in children <17 years of age; safety and efficacy not established.115


Safety and efficacy of fixed-combination ointment or suspension containing betamethasone dipropionate and calcipotriene not established in pediatric patients.116 117


Adverse effects consistent with corticosteroid use have been observed in patients with diaper dermatitis treated with preparations containing betamethasone dipropionate in fixed combination with clotrimazole.115


Tight-fitting diapers or plastic pants should not be used on a child being treated with betamethasone valerate cream in the diaper area, since they may constitute occlusive dressings.112 113 114


Children are more susceptible to topical corticosteroid-induced HPA-axis suppression and Cushing’s syndrome than mature individuals because of a greater skin surface area-to-body weight ratio, especially when topical corticosteroids are applied to >20% of body surface area.101 102 103 104 105 106 108 112 113 114 116 117 b e The risk of adrenal suppression appears to increase with decreasing age.101 102 104 105 (See Systemic Effects under Cautions.)


Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol concentrations, lack of response to corticotropin (ACTH) stimulation.101 102 104 105 106 108 112 113 114


Children are also at greater risk of glucocorticosteroid insufficiency during and/or after withdrawal of treatment.108 e


Intracranial hypertension has occurred in children; manifestations include bulging fontanelles, headaches, and bilateral papilledema.101 102 104 105 106 108 112 113 114


Children are at greater risk of adverse atrophic dermatologic effects.


Striae has been reported in children treated inappropriately with topical corticosteroids.105 108


Topical corticosteroid therapy in children should be limited to the minimum amount necessary for therapeutic efficacy; chronic topical corticosteroid therapy may interfere with growth and development.101 102 103 104 105 108 112 113 114 b


Geriatric Use

Insufficient experience with preparations containing betamethasone dipropionate in fixed combination with clotrimazole in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults; skin atrophy and ulceration have been reported.115


Use with caution in geriatric patients with thinning skin; do not use with occlusion and/or for treatment of diaper dermatitis.115 e


No substantial differences in safety or efficacy of fixed-combination ointment or suspension containing betamethasone dipropionate and calcipotriene observed in geriatric patients relative to younger adults.116 117


Common Adverse Effects


Burning, stinging, itching, irritation, dry skin, erythema, folliculitis, hypertrichosis.101 103 104 105 108 112 114 113 115 b


Children: skin atrophy (telangiectasia, bruising, shininess), paresthesia (burning), erythema, erythematous rash.101 102 103 104


Interactions for Betamethasone Dipropionate


Specific Drugs and Laboratory Tests









Drug or Test



Interaction



Corticosteroids



Potential pharmacologic interaction with other corticosteroid-containing preparations101 102 103 104 115 116 117



Nitroblue-tetrazolium test for bacterial infection



Concurrent use of corticosteroids reportedly may result in false-negative resultse


Betamethasone Dipropionate Pharmacokinetics


Absorption


Bioavailability


Topically applied betamethasone dipropionate and valerate can be absorbed through normal intact skin.101 102 103 104 105 106 108 112 113 114 115 116 b


Extent of systemic absorption of the drug is increased with lotion preparations and those formulated with an optimized (augmented) vehicle.101 102 103 104 105 106 b


Percutaneous penetration can be altered by using different vehicles and increases with decreasing age.101 102 103 104 105 106 108 112 113 114 115 116 b


Percutaneous penetration also can be increased by use of occlusive dressings and by presence of inflammation and/or other disease of the epidermal barrier (e.g., psoriasis, eczema).101 102 103 104 105 106 108 112 113 114 115 116 117 b


Distribution


Extent


Not known whether topical betamethasone is distributed into milk.101

Bepreve


Generic Name: Bepotastine Besilate
Class: Antiallergic Agents
Chemical Name: 4-[(S)-(4-chlorophenyl)-2-pyridinylmethoxy]-,benzene sulfonate (1:1); (2) (+)-4-{4-[(S)-(4-Chlorophenyl)(pyridin-2-yl)methoxy]piperidin-1-yl}butanoic acid monobenzenesulfonate.
Molecular Formula: C21H25ClN2O3.C6H6O3S.547.10
CAS Number: 190786-44-8

Introduction

Histamine H 1-receptor antagonist with mass-cell stabilizing activity.1 2 3 5


Uses for Bepreve


Allergic Conjunctivitis


Symptomatic treatment of ocular itching associated with allergic conjunctivitis.1 3 7 8 9 10


Bepreve Dosage and Administration


Administration


Ophthalmic Administration


Apply topically to the eye as an ophthalmic solution.1 2 3 5 6


Remove soft contact lenses prior to administration of each dose (since benzalkonium chloride may be absorbed by the lenses); may reinsert lenses after 10 minutes following administration if eyes are not red.1 5


Avoid contamination of the solution container.1 5


Dosage


Available as bepotastine besilate; dosage expressed in terms of the salt.1


Pediatric Patients


Allergic Conjunctivitis

Ophthalmic

Children ≥2 years of age: 1 drop of a 1.5% solution in the affected eye(s) twice daily.1


Adults


Allergic Conjunctivitis

Ophthalmic

1 drop of a 1.5% solution in the affected eye(s) twice daily.1 5


Cautions for Bepreve


Contraindications



  • Manufacturer states none known.1



Warnings/Precautions


Administration


For topical ophthalmic use only.1


Proper Handling to Avoid Contamination


To avoid contamination of the dropper tip and solution, do not to touch the eyelids or surrounding areas with the dropper tip.1


Close container tightly when not in use.1


Contact Lenses


Remove contact lenses prior to administration of each dose, since benzalkonium chloride preservative may be absorbed by soft contact lenses; lenses may be reinserted after 10 minutes following administration if eyes are not red; patient should not wear contact lenses if eyes are red.1 5 Not indicated for contact lens-related ocular irritation.1 5


Specific Populations


Pregnancy

Category C.1 5


Lactation

Distributed into milk in rats following oral administration.1


Not known whether bepotastine besilate distributes into human milk following topical application to the eye.1 Use caution.1


Pediatric Use

Safety and efficacy not established in pediatric patients <2 years of age.1 Efficacy in pediatric patients <10 years of age was extrapolated from clinical trials conducted in pediatric patients >10 years of age and adults.1


Geriatric Use

No overall differences in efficacy or safety observed between geriatric and younger patients.1


Common Adverse Effects


Mild taste following instillation,1 3 6 ocular irritation, headache, nasopharyngitis.1 2 3 10


Interactions for Bepreve


Minimally metabolized by CYP isoenzymes.1


Drugs Metabolized by Hepatic Microsomal Enzymes


Low potential for drug interactions via inhibition of CYP isoenzymes 3A4, 2C9, and 2C19.1


Effect on metabolism of substrates of CYP isoenzymes 1A2, 2C8, and 2D6 not established.1


Bepreve Pharmacokinetics


Absorption


Bioavailability


Peak plasma concentrations achieved approximately 1–2 hours after instillation.1


Distribution


Plasma Protein Binding


Approximately 55%.1


Elimination


Metabolism


Minimally metabolized by CYP isoenzymes.1


Elimination Route


Excreted principally in urine as unchanged drug (75–90%).1


Stability


Storage


Ophthalmic


Solution

15–25°C.1


ActionsActions



  • Inhibits the release of histamine and other mediators (e.g., leukotrienes, platelet activating factor [PAF]) involved in allergic reactions.1 2 3 5




  • Exhibits mast-cell stabilizing activity.1 2 3 5




  • Inhibits eosinophil migration to and activation at inflammatory sites.2



Advice to Patients



  • Importance of learning and adhering to proper administration techniques to avoid contamination of the solution.1 5




  • Importance of removing contact lenses prior to administration of each ophthalmic dose, since benzalkonium chloride preservative may be absorbed by soft lenses; may reinsert contact lenses after 10 minutes following administration if eyes are not red; importance of not wearing contact lenses if eyes are red.1 5




  • Not indicated for contact lens-related ocular irritation.1 5




  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.1




  • Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.1




  • Importance of informing patients of other important precautionary information.




  • (See Cautions.)1



Preparations


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.













Bepotastine Besilate

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Ophthalmic



Solution



1.5%



Bepreve



Ista


Comparative Pricing


This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.


Bepreve 1.5% Solution (ISTA PHARMACEUTICALS): 10/$189.98 or 30/$529.97



Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.


The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions October 2010. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.




References



1. Ista Pharmaceuticals. Bepreve(bepotastine besilate) ophthalmic solution prescribing information. Irvine, CA; 2009 Aug. (



2. Abelson MB, Torkildsen GL, Williams JI et al. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solution 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo controlled, conjunctival allergen challenge assessment in adults and children. Clin Ther. 2009; 31:1908-21. [PubMed 19843481]



3. Anon. Bepotastine (Bepreve)—An ophthalmic H1 antihistamine. Med Lett. 2010; 52:8-12.



4. Protzko EE, Gomes PJ, Williams JI et al. The ocular comfort and safety of the novel anti-Histamine bepotastine besilate ophthalmic solution 1.5% in a healthy pediatric population. J Allergy Clin Immunol. 2009; (Suppl 2): S50.



5. Hussar DA, Abbas CA. New drugs: asenapine, iloperidone, and bepotastine besilate. J Am Pharm Assoc. 2010; 50:107-10.



6. Gow JA, Protzko EE, Gomes PJ et al. Safety of the antihistamine bepotastine besilate ophthalmic solution in a healthy pediatric population from 3 to 9 years of age. Poster presented at: 35th Symposium on Cataract, IOL, and Refractive Surgery of the American Society of Cataract and Refractive Surgery. San Francisco, CA: 2009 April 4-8. Abstract 559458.



7. Meier EJ, Macejko TT, Bergmann MT et al. Bepotastine besilate ophthalmic solution 1.0% provides rapid relief of rhinorrhea, total non-ocular symptoms, tearing, and ciliary and episcleral hyperemia following dosing in a multi-site clinical model of allergic conjunctivitis. J Allergy Clin Immunol. 2009; 123 (Suppl): S57.



8. Torkildsen GL, Gomes PJ, Williams JI et al. Bepotastine besilate ophthalmic solution 1.5% reduces ocular itching in a clinical model of allergic conjunctivitis. J Allergy Clin Immunol. 2009; 123 (Suppl): S57.



9. Macejko TT, Meier EJ, Bergmann MT et al. Bepotastine besilate ophthalmic solution 1.5% for up to 8 hours following dosing reduces total non-ocular symptoms, rhinorrhea, and tearing in a multi-site clinical model of allergic conjunctivitis. J Allergy Clin Immunol. 2009; 123 (Suppl):S57.



10. Bergmann MT, Gomes PJ, Williams JI et al. Bepotastine besilate ophthalmic solution 1.5% reduces ocular itching in a multisite clinical model of allergic conjunctivitis. Poster presented at the 35th Symposium on Cataract, IOL, and Refractive Surgery of the American Society of Cataract and Refractive Surgery. San Francisco, CA: 2009 April 4-8. Abstract 559520.



11. ISTA Pharmaceuticals, Irvine, CA: Personal communication.



12. Wadhwa SD. Medical review(s) for bepotastine besilate ophthalmic solution 1.5% (Bepreve), application number 22-228. Rockville, MD: US Food and Drug Administration; 2009 Apr 27. From FDA website ().



More Bepreve resources


  • Bepreve Side Effects (in more detail)
  • Bepreve Use in Pregnancy & Breastfeeding
  • Bepreve Support Group
  • 10 Reviews for Bepreve - Add your own review/rating


  • Bepreve Prescribing Information (FDA)

  • Bepreve Advanced Consumer (Micromedex) - Includes Dosage Information

  • Bepreve Eye Drops MedFacts Consumer Leaflet (Wolters Kluwer)

  • Bepreve Consumer Overview



Compare Bepreve with other medications


  • Conjunctivitis, Allergic

Berinert


Generic Name: complement C1 esterase inhibitor (KOM ple ment C1 ES ter ase in HIB it or)

Brand Names: Berinert, Cinryze


What is complement C1 esterase inhibitor?

Complement C1 esterase inhibitor is a man-made form of a protein that occurs naturally in the blood stream and helps control inflammation in the body. In people with hereditary angioedema, complement C1 esterase inhibitor does not function properly or occurs in low levels.


Complement C1 esterase inhibitor is used in people with hereditary angioedema. The Berinert brand of this medication is used to treat attacks of angioedema. The Cinryze brand is used to prevent attacks of angioedema.


Complement C1 esterase inhibitor may also be used for purposes not listed in this medication guide.


What is the most important information I should know about complement C1 esterase inhibitor?


You should not use this medication if have ever had a life-threatening allergic reaction to complement C1 esterase inhibitor.

Before you receive complement C1 esterase inhibitor, tell your doctor if you have a history of stroke or blood clot.


Do not give this medication to a child without medical advice.

You may be shown how to use Cinryze in an IV at home. This medication comes with patient instructions for safe and effective use. Follow all directions carefully. Ask your doctor or pharmacist if you have any questions.


Do not self-inject this medicine if you do not fully understand how to give the injection and properly dispose of used needles, IV tubing, and other items used to inject the medicine. Be sure you understand how to properly mix and store the medication. Stop your IV infusion and get emergency medical help if you have any of these signs of an allergic reaction: hives; wheezing or difficult breathing; feeling like you might pass out; or swelling of your face, lips, tongue, or throat.

Other serious side effects may include sudden numbness or weakness, chest pain, confusion, pain or swelling, and problems with vision, speech, or balance.


Complement C1 esterase inhibitor is made from human plasma (part of the blood) which may contain viruses and other infectious agents. Donated plasma is tested and treated to reduce the risk of it containing infectious agents, but there is still a small possibility it could transmit disease. Talk with your doctor about the risks and benefits of using this medication.

What should I discuss with my health care provider before using complement C1 esterase inhibitor?


You should not use this medication if have ever had a life-threatening allergic reaction to rugae.

To make sure you can safely use complement C1 esterase inhibitor, tell your doctor if you have a history of stroke or blood clot.


FDA pregnancy category C. It is not known whether complement C1 esterase inhibitor will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant while using this medication. It is not known whether complement C1 esterase inhibitor passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby. Complement C1 esterase inhibitor is made from human plasma (part of the blood) which may contain viruses and other infectious agents. Donated plasma is tested and treated to reduce the risk of it containing infectious agents, but there is still a small possibility it could transmit disease. Talk with your doctor about the risks and benefits of using this medication. Do not give this medication to a child without medical advice.

How should I use complement C1 esterase inhibitor?


Use exactly as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.


Complement C1 esterase inhibitor is injected into a vein through an IV. A healthcare provider will give you a Berinert injection in a clinic or hospital setting. You may be shown how to use Cinryze in an IV at home. Do not self-inject this medicine if you do not fully understand how to give the injection and properly dispose of used needles, IV tubing, and other items used to inject the medicine.


This medication comes with patient instructions for safe and effective use. Ask your doctor or pharmacist if you have any questions.


Complement C1 esterase inhibitor is a powder medicine that must be mixed with a liquid (diluent) before using it. If you are using Cinryze home, you will need to use two vials of Cinryze to make up a single dose. Follow all directions carefully. Be sure you understand how to properly mix and store the medicine.


Gently swirl but do not shake the mixed medicine or you may ruin it. Prepare your dose only when you are ready to give yourself an injection.

Mixed Berinert should be clear and colorless. Mixed Cinryze should be clear or slightly blue in color. Do not use the mixed medicine if it has changed colors, is cloudy, or has any particles in it. Call your doctor for a new prescription.


Cinryze is usually given every 3 or 4 days to prevent angioedema attacks. An IV infusion takes about 10 minutes to complete.


Complement C1 esterase inhibitor contains no preservative. Once you have pierced the rubber top of a vial with a needle, you must use that vial right away or throw it away.

Each single use vial (bottle) of this medicine is for one use only. Throw away after one use, even if there is still some medicine left in it after injecting your dose.


Use each disposable needle only one time. Throw away used needles in a puncture-proof container (ask your pharmacist where you can get one and how to dispose of it). Keep this container out of the reach of children and pets.


Store the unmixed dry powder in a refrigerator or in a dark cool place. Keep the medicine protected from light and do not allow it to freeze. Throw away any unused vial after the expiration date on the label has passed. After mixing Berinert with the diluent, use it right away or store the mixture at room temperature and use it within 8 hours. After mixing Cinryze with the diluent, use it right away or store the mixture at room temperature and use it within 3 hours.

What happens if I miss a dose?


Use the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not use extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

Overdose symptoms may include sudden headache, numbness, weakness, or problems with your speech, vision, or balance.


What should I avoid while using complement C1 esterase inhibitor?


Follow your doctor's instructions about any restrictions on food, beverages, or activity.


Complement C1 esterase inhibitor side effects


Stop your IV infusion and get emergency medical help if you have any of these signs of an allergic reaction: hives; wheezing or difficult breathing; feeling like you might pass out; or swelling of your face, lips, tongue, or throat. Call your doctor at once if you have any other serious side effect, such as:

  • new or worsening pain;




  • sudden numbness or weakness, especially on one side of the body;




  • sudden severe headache, confusion, problems with vision, speech, or balance;




  • stomach pain or swelling;




  • chest pain, sudden cough, rapid breathing, fast heart rate; or




  • pain, swelling, warmth, or redness in one or both legs.



Less serious side effects may include:



  • nausea, vomiting, stomach pain;




  • altered sense of taste;




  • cold symptoms such as stuffy nose, sneezing, sore throat;




  • mild itching or rash; or




  • mild headache.



This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect complement C1 esterase inhibitor?


There may be other drugs that can interact with this medication. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.



More Berinert resources


  • Berinert Side Effects (in more detail)
  • Berinert Use in Pregnancy & Breastfeeding
  • Berinert Support Group
  • 0 Reviews for Berinert - Add your own review/rating


  • Berinert Advanced Consumer (Micromedex) - Includes Dosage Information

  • Berinert Consumer Overview

  • Berinert MedFacts Consumer Leaflet (Wolters Kluwer)

  • Berinert Prescribing Information (FDA)

  • Cinryze Prescribing Information (FDA)

  • Cinryze MedFacts Consumer Leaflet (Wolters Kluwer)

  • Cinryze Consumer Overview

  • Cinryze Monograph (AHFS DI)



Compare Berinert with other medications


  • Hereditary Angioedema


Where can I get more information?


  • Your doctor or pharmacist can provide more information about complement C1 esterase inhibitor.

See also: Berinert side effects (in more detail)


Besivance


Generic Name: besifloxacin (Ophthalmic route)

be-si-FLOX-a-sin

Commonly used brand name(s)

In the U.S.


  • Besivance

Available Dosage Forms:


  • Suspension

Therapeutic Class: Antibiotic


Chemical Class: Fluoroquinolone


Uses For Besivance


Besifloxacin ophthalmic (eye) preparation is used to treat infections of the eye, such as bacterial conjunctivitis. Besifloxacin belongs to a group of medicines called fluoroquinolone antibiotics. It works by killing bacteria that cause conjunctivitis.


This medicine is available only with your doctor's prescription.


Before Using Besivance


In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:


Allergies


Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.


Pediatric


Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of besifloxacin in children. However, safety and efficacy have not been established in children younger than 1 year of age.


Geriatric


Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of besifloxacin in the elderly.


Pregnancy








Pregnancy CategoryExplanation
All TrimestersCAnimal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women.

Breast Feeding


There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.


Interactions with Medicines


Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.


Interactions with Food/Tobacco/Alcohol


Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.


Proper Use of Besivance


Your doctor will tell you how much of this medicine to use and how often. Do not use more medicine or use it more often than your doctor tells you to. This medicine is not for long-term use.


To use the eye drops:


  • First, wash your hands. Then turn the closed bottle upside down and shake it one time before putting the medicine in your eye. Remove the cap with the bottle still being held upside down.

  • Tilt your head back and, pressing your finger gently on the skin just beneath the lower eyelid, pull the lower eyelid away from the eye to make a space. Drop the medicine into this space. Let go of the eyelid and gently close the eye. Do not blink. Keep the eye closed for 1 or 2 minutes to allow the medicine to cover the eye.

  • If you think you did not get the drop of medicine into your eye properly, repeat the directions with another drop.

  • To keep the medicine as germ-free as possible, do not touch the applicator tip to any surface (including the eye). Also, keep the container tightly closed.

To help clear up your eye infection completely, keep using this medicine for the full time of treatment, even if you feel better after the first few doses. Your infection may not clear up if you stop using the medicine too soon. Do not miss any doses.


Dosing


The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.


The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.


  • For ophthalmic dosage form (eye drops):
    • For bacterial conjunctivitis:
      • Adults and children 1 year of age and older—Put one drop in the affected eye three times a day, with each dose at least four to twelve hours apart.

      • Infants younger than 1 year of age—Use and dose must be determined by your doctor.



Missed Dose


If you miss a dose of this medicine, apply it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule.


Storage


Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.


Keep out of the reach of children.


Do not keep outdated medicine or medicine no longer needed.


Ask your healthcare professional how you should dispose of any medicine you do not use.


Precautions While Using Besivance


If your eye infection does not improve, or if it becomes worse, check with your doctor.


Stop using this medicine and check with your doctor right away if you have a rash, itching, or red or swollen skin around the eye or eyelid. These may be symptoms of an allergic reaction.


Do not wear contact lenses while you are using this medicine to avoid further eye irritation.


Besivance Side Effects


Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.


Check with your doctor immediately if any of the following side effects occur:


Less common
  • Blurred vision

  • eye pain

  • itching of the eye

  • red, sore eyes

  • swelling of the eye or eyelid

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:


Less common
  • Headache

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.


Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: Besivance side effects (in more detail)



The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.


The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.


More Besivance resources


  • Besivance Side Effects (in more detail)
  • Besivance Use in Pregnancy & Breastfeeding
  • Besivance Support Group
  • 1 Review for Besivance - Add your own review/rating


  • Besivance Prescribing Information (FDA)

  • Besivance Monograph (AHFS DI)

  • Besivance Drops MedFacts Consumer Leaflet (Wolters Kluwer)

  • Besivance Consumer Overview



Compare Besivance with other medications


  • Conjunctivitis, Bacterial
  • Ophthalmic Surgery

betamethasone and clotrimazole topical


Generic Name: betamethasone and clotrimazole topical (bay ta METH a sone and kloe TRIM a zole)

Brand Names: Lotrisone


What is betamethasone and clotrimazole topical?

Clotrimazole is an antifungal antibiotic that treats or prevents infection caused by fungus.


Betamethasone is a topical steroid that reduces itching, swelling, and redness of the skin.


The combination of betamethasone and clotrimazole topical is used to treat fungal skin infections such as athlete's foot, jock itch, and ringworm.


Betamethasone and clotrimazole topical may also be used for other purposes not listed in this medication guide.


What is the most important information I should know about betamethasone and clotrimazole topical?


Do not cover treated skin areas with a bandage or tight clothing, unless your doctor has told you to. Do not use this medication on a child younger than 17 years old. Children are more likely to absorb the steroid through the skin. Never use betamethasone and clotrimazole to treat diaper rash. It may take up to 1 or 2 weeks of using this medicine before your symptoms improve. For best results, keep using the medication as directed. Talk with your doctor if your groin symptoms do not improve after 1 week, or if your foot symptoms do not improve after 2 weeks of treatment.

What should I discuss with my healthcare provider before using betamethasone and clotrimazole topical?


Do not use this medication if you have ever had an allergic reaction to:

  • betamethasone (such as Betaderm, Diprolene, Luxiq, Taclonex, Uticort, Valisone);




  • clotrimazole (such as Desenex, Lotrimin, Mycelex);




  • other topical steroid medications such as alclometasone (Aclovate), clobetasol (Olux, Temovate), desonide (Desowen), desoximetasone (Topicort), diflorasone (Florone, Psorcon), fluocinolone (Capex, Dermotic, Fluonid, Fluorosyn, Synalar), fluocinonide (Dermacin, Lidex), fluticasone (Cutivate), halcinonide (Halog), halobetasol (Ultravate), mometasone (Elocon), triamcinolone (Aristocort, Kenalog); or




  • other topical antibiotics such as econazole (Spectazole), ketoconazole (Kuric, Nizoral), miconazole (Cruex, Desenex, Fungoid, Lotrimin, Micatin, Monistat), sertaconazole (Ertaczo), or sulconazole (Exelderm).



Before using betamethasone topical, tell your doctor if you are allergic to any drugs, or if you have any type of skin infection. You may not be able to use this medication, or you may need a dose adjustment or special tests during treatment.


FDA pregnancy category C. This medication may be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment. It is not known whether betamethasone and clotrimazole passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby. Do not use this medication on a child younger than 17 years old. Children are more likely to absorb the steroid through the skin. Never use betamethasone and clotrimazole to treat diaper rash.

How should I use betamethasone and clotrimazole topical?


Use this medication exactly as it was prescribed for you. Do not use the medication in larger amounts, or use it for longer than recommended by your doctor. Follow the instructions on your prescription label.


This medication comes with patient instructions for safe and effective use. Follow these directions carefully. Ask your doctor or pharmacist if you have any questions.


Wash your hands before and after applying this medicine. Shake the lotion form of this medication well just before you use it.

Apply a thin layer of the medication and rub it in completely.


Do not cover treated skin areas with a bandage or tight clothing, unless your doctor has told you to.

After applying this medication, allow your skin to dry completely before dressing. Wear loose-fitting clothing while you are treating jock itch. If you are treating athlete's foot, wear clean cotton socks and keep your feet as dry as possible.


Do not use betamethasone and clotrimazole for longer than 2 weeks for jock itch or 4 weeks for athlete's foot, unless your doctor has told you to. It may take up to 1 or 2 weeks of using this medicine before your symptoms improve. For best results, keep using the medication as directed. Talk with your doctor if your groin symptoms do not improve after 1 week, or if your foot symptoms do not improve after 2 weeks of treatment. Store this medicine at room temperature away from moisture and heat. Keep the tube or bottle capped and tightly closed when not in use.

What happens if I miss a dose?


Use the medication as soon as you remember the missed dose. If it is almost time for your next dose, skip the missed dose and use the medicine at your next regularly scheduled time. Do not use extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention if you think you have used too much of this medicine. An overdose of betamethasone and clotrimazole applied to the skin is not expected to produce life-threatening symptoms.

What should I avoid while using betamethasone and clotrimazole topical?


Avoid getting this medication in your eyes, mouth, and nose, or on your lips. If it does get into any of these areas, wash with water. Do not use betamethasone and clotrimazole topical on sunburned, windburned, dry, chapped, irritated, or broken skin.

Avoid wearing tight-fitting clothing that doesn't allow air circulation. Until the infection is healed, wear clothing that is made of natural fibers such as cotton.


Betamethasone and clotrimazole topical side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using this medication and call your doctor at once if you have any of these signs that you may be absorbing betamethasone topical through your skin or gums:

  • swelling, redness, or any signs of new infection;




  • severe burning or stinging of treated skin;




  • weight gain, rounding of the face;




  • increased thirst or hunger, urinating more than usual; or




  • anxiety, depressed mood.



Less serious side effects may include:



  • mild skin itching or irritation;




  • dry skin;




  • changes in skin color;




  • increased acne; or




  • scarring or thinning of the skin.



This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.


Betamethasone and clotrimazole topical Dosing Information


Usual Adult Dose for Tinea Corporis:

Apply to affected area twice a day for 2 weeks.

Usual Adult Dose for Tinea Cruris:

Apply to affected area twice a day for 2 weeks.

Usual Adult Dose for Tinea Pedis:

Apply to affected area twice a day for 4 weeks.

Usual Pediatric Dose for Tinea Corporis:

Child > 12 years: Apply to affected area twice a day for 2 weeks.

Usual Pediatric Dose for Tinea Cruris:

Child > 12 years: Apply to affected area twice a day for 2 weeks.

Usual Pediatric Dose for Tinea Pedis:

Child > 12 years: Apply to affected area twice a day for 4 weeks.


What other drugs will affect betamethasone and clotrimazole topical?


It is not likely that other drugs you take orally or inject will have an effect on topically applied betamethasone and clotrimazole. But many drugs can interact with each other. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.



More betamethasone and clotrimazole topical resources


  • Betamethasone and clotrimazole topical Dosage
  • Betamethasone and clotrimazole topical Use in Pregnancy & Breastfeeding
  • Betamethasone and clotrimazole topical Drug Interactions
  • Betamethasone and clotrimazole topical Support Group
  • 0 Reviews for Betamethasone and clotrimazole - Add your own review/rating


Compare betamethasone and clotrimazole topical with other medications


  • Tinea Corporis
  • Tinea Cruris
  • Tinea Pedis


Where can I get more information?


  • Your pharmacist can provide more information about betamethasone and clotrimazole topical.


Betamethasone Cream Augmented




Generic Name: betamethasone dipropionate

Dosage Form: cream, augmented
Betamethasone Dipropionate Cream, 0.05% (Augmented*)

(potency expressed as betamethasone)


*Vehicle augments the penetration of the steroid.


For Dermatologic Use Only - Not for Ophthalmic Use



Betamethasone Cream Augmented Description


Betamethasone dipropionate cream, 0.05% (augmented) contains betamethasone dipropionate, USP, a synthetic adrenocorticosteroid, for dermatologic use in an emollient base. Betamethasone, an analog of prednisolone, has a high degree of corticosteroid activity and a slight degree of mineralocorticoid activity. Betamethasone dipropionate is the 17, 21-dipropionate ester of betamethasone.


Chemically, betamethasone dipropionate is 9-fluoro-11β,17,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate, with the empirical formula C28H37FO7, a molecular weight of 504.6, and the following structural formula :



Betamethasone dipropionate is a white to creamy white, odorless crystalline powder, insoluble in water.


Each gram of betamethasone dipropionate cream, 0.05% (augmented) contains: 0.643 mg betamethasone dipropionate USP (equivalent to 0.5 mg betamethasone) in an emollient cream base of purified water USP; chlorocresol NF; propylene glycol USP; white petrolatum USP; white wax NF; cyclomethicone NF; sorbitol solution USP; glyceryl oleate/propylene glycol; ceteareth-30; carbomer homopolymer NF; and sodium hydroxide NF.



Betamethasone Cream Augmented - Clinical Pharmacology


The corticosteroids are a class of compounds comprising steroid hormones secreted by the adrenal cortex and their synthetic analogs. In pharmacologic doses, corticosteroids are used primarily for their anti-inflammatory and/or immunosuppressive effects.


Topical corticosteroids, such as betamethasone dipropionate, are effective in the treatment of corticosteroid-responsive dermatoses primarily because of their anti-inflammatory, antipruritic, and vasoconstrictive actions. However, while the physiologic, pharmacologic, and clinical effects of the corticosteroids are well known, the exact mechanisms of their actions in each disease are uncertain. Betamethasone dipropionate, a corticosteroid, has been shown to have topical (dermatologic) and systemic pharmacologic and metabolic effects characteristic of this class of drugs.



Pharmacokinetics:


The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. (See DOSAGE AND ADMINISTRATION section.)


Topical corticosteroids can be absorbed through normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. (See DOSAGE AND ADMINISTRATION section.)


Once absorbed through the skin, topical corticosteroids enter pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees, are metabolized primarily in the liver and excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.


Betamethasone dipropionate cream, 0.05% (augmented) was applied once daily at 7 grams per day for 1 week to diseased skin, in adult patients with psoriasis or atopic dermatitis, to study its effects on the hypothalamic-pituitary-adrenal (HPA) axis. The results suggested that the drug caused a slight lowering of adrenal corticosteroid secretion, although in no case did plasma cortisol levels go below the lower limit of the normal range.


Sixty-seven pediatric patients ages 1 to 12 years, with atopic dermatitis, were enrolled in an open-label, hypothalamic-pituitary-adrenal (HPA) axis safety study.Betamethasone dipropionate cream, 0.05% (augmented) was applied twice daily for 2 to 3 weeks over a mean body surface area of 58% (range 35% to 95%). In 19 of 60 (32%) evaluable patients, adrenal suppression was indicated by either a ≤ 5 mcg/dL pre-stimulation cortisol, or a cosyntropin post-stimulation cortisol ≤ 8 mcg/dL and/or an increase of < 7 mcg/dL from the baseline cortisol. Studies performed with betamethasone dipropionate cream, 0.05% (augmented) indicate that it is in the high range of potency as compared with other topical corticosteroids.



Indications and Usage for Betamethasone Cream Augmented


Betamethasone dipropionate cream, 0.05% (augmented) is a high-potency corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years and older.



Contraindications


Betamethasone dipropionate cream, 0.05% (augmented) is contraindicated in patients who are hypersensitive to betamethasone dipropionate, to other corticosteroids, or to any ingredient in this preparation.



Precautions



General


Systemic absorption of topical corticosteroids has produced reversible HPA axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.


Conditions which augment systemic absorption include the application of the more potent corticosteroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Use of more than one corticosteroid-containing product at the same time may increase total systemic glucocorticoid exposure. (See DOSAGE AND ADMINISTRATION section.)


Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.


Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. In an open-label pediatric study of 60 evaluable patients, of the 19 who showed evidence of suppression 4 patients were tested 2 weeks after discontinuation of betamethasone dipropionate cream, 0.05% (augmented) and 3 of the 4 (75%) had complete recovery of HPA axis function. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.


Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity. (See PRECAUTIONS: Pediatric Use:.)


If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.


In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.



Information For Patients:


Patients using topical corticosteroids should receive the following information and instructions. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.


  1. This medication is to be used as directed by the physician and should not be used longer than the prescribed time period. It is for external use only. Avoid contact with the eyes.

  2. Patients should be advised not to use this medication for any disorder other than that for which it was prescribed.

  3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive. (See DOSAGE AND ADMINISTRATION section.)

  4. Patients should report any signs of local adverse reactions.

  5. Other corticosteroid-containing products should not be used with betamethasone dipropionate cream, 0.05% (augmented) without first talking to your physician.


Laboratory Tests:


The following tests may be helpful in evaluating HPA axis suppression:


Urinary free cortisol test

ACTH stimulation test



Carcinogenesis, Mutagenesis, and Impairment of Fertility:


Long-term animal studies have not been performed to evaluate the carcinogenic potential of betamethasone dipropionate.


Betamethasone was negative in the bacterial mutagenicity assay (Salmonella typhimurium and Escherichia coli), and in the mammalian cell mutagenicity assay (CHO/HGPRT). It was positive in the in-vitro human lymphocyte chromosome aberration assay, and equivocal in the in-vivo mouse bone marrow micronucleus assay. This pattern of response is similar to that of dexamethasone and hydrocortisone.


Reproductive studies with betamethasone dipropionate carried out in rabbits at doses of 1.0 mg/kg by the intramuscular route and in mice up to 33 mg/kg by the intramuscular route indicated no impairment of fertility except for dose-related increases in fetal resorption rates in both species. These doses are approximately 5- and 38-fold the human dose based on a mg/m2 comparison, respectively.



Pregnancy:


Teratogenic Effects: Pregnancy Category C:

Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels.


Betamethasone dipropionate has been shown to be teratogenic in rabbits when given by the intramuscular route at doses of 0.05 mg/kg.This dose is approximately 0.2-fold the maximum human dose based on a mg/m2 comparison. The abnormalities observed included umbilical hernias, cephalocele and cleft palates.


Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.



Nursing Mothers:


It is not known whether topical administration of corticosteroids can result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.



Pediatric Use:


Use of betamethasone dipropionate cream, 0.05% (augmented) in pediatric patients 12 years of age and younger is not recommended. (See CLINICAL PHARMACOLOGY and ADVERSE REACTIONS sections.) In an open-label study, 19 of 60 (32%) evaluable pediatric patients (aged 3 months-12 years old) using betamethasone dipropionate cream, 0.05% (augmented) for treatment of atopic dermatitis demonstrated HPA axis suppression. The proportion of patients with adrenal suppression in this study was progressively greater, the younger the age group. (See CLINICAL PHARMACOLOGY: Pharmacokinetics:)


Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing’s syndrome than mature patients because of a larger skin surface area to body weight ratio.The study described above supports this premise, as adrenal suppression in 9-12 year olds, 6-8 year olds, 2-5 year olds, and 3 months-1 year old was 17%, 32%, 38% and 50% respectively.


Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Chronic corticosteroid therapy may interfere with the growth and development of children.



Geriatric Use:


Clinical studies of betamethasone dipropionate cream, 0.05% (augmented) included 104 subjects who were 65 years of age and over and 8 subjects who were 75 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients. However, greater sensitivity of some older individuals cannot be ruled out.



Adverse Reactions


The only local adverse reaction reported to be possibly or probably related to treatment with betamethasone dipropionate cream, 0.05% (augmented) during adult controlled clinical studies was stinging. It occurred in 1 patient, 0.4%, of the 242 patients or subjects involved in the studies.


Adverse reactions reported to be possibly or probably related to treatment with betamethasone dipropionate cream, 0.05% (augmented) during a pediatric clinical study include signs of skin atrophy (telangiectasia, bruising, shininess). Skin atrophy occurred in 7 of 67 (10%) patients, involving all age groups from 3 months - 12 years of age.


The following local adverse reactions are reported infrequently when topical corticosteroids are used as recommended. These reactions dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, miliaria.


Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients.



Overdosage


Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects. (See PRECAUTIONS.)



Betamethasone Cream Augmented Dosage and Administration


Apply a thin film of betamethasone dipropionate cream, 0.05% (augmented) to the affected skin areas once or twice daily. Treatment with betamethasone dipropionate cream, 0.05% (augmented) should be limited to 45 g per week.


Betamethasone dipropionate cream, 0.05% (augmented) is not to be used with occlusive dressings.



How is Betamethasone Cream Augmented Supplied


Betamethasone dipropionate cream, 0.05% (augmented) is supplied in 15 g (NDC 68462-290-17) and 50 g (NDC 68462-290-52); boxes of one.



Store at 25°C (77°F); excursions permitted to 15 - 30°C (59 - 86°F) [see USP Controlled Room Temperature].



Manufactured:


Glenmark Generics Ltd.

Village: Kishanpura, Baddi Nalagarh Road

District: Solan, Himachal Pradesh - 174101, India


Manufactured for:



Glenmark Generics Inc., USA

Mahwah, NJ 07430


Questions? 1 (888)721-7115

www.glenmarkgenerics.com


February 2011



Principal Display Panel












BETAMETHASONE DIPROPIONATE 
betamethasone dipropionate  cream










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)68462-290
Route of AdministrationTOPICALDEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
BETAMETHASONE DIPROPIONATE (BETAMETHASONE)BETAMETHASONE DIPROPIONATE0.5 mg  in 1 g






















Inactive Ingredients
Ingredient NameStrength
CHLOROCRESOL 
PROPYLENE GLYCOL 
SODIUM HYDROXIDE 
SORBITOL 
PETROLATUM 
WHITE WAX 
CARBOMER HOMOPOLYMER TYPE C 
CYCLOMETHICONE 
CETEARETH-30 


















Product Characteristics
Color    Score    
ShapeSize
FlavorImprint Code
Contains      














Packaging
#NDCPackage DescriptionMultilevel Packaging
168462-290-1715 g In 1 TUBENone
268462-290-5250 g In 1 TUBENone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
ANDAANDA07893009/23/2008


Labeler - Glenmark Generics Inc., USA (835917282)









Establishment
NameAddressID/FEIOperations
Glenmark Pharmaceuticals Limited676115028ANALYSIS, MANUFACTURE
Revised: 03/2011Glenmark Generics Inc., USA

More Betamethasone Cream Augmented resources


  • Betamethasone Cream Augmented Use in Pregnancy & Breastfeeding
  • Betamethasone Cream Augmented Drug Interactions
  • Betamethasone Cream Augmented Support Group
  • 13 Reviews for Betamethasone Augmented - Add your own review/rating


Compare Betamethasone Cream Augmented with other medications


  • Atopic Dermatitis
  • Dermatitis
  • Dermatological Disorders
  • Lichen Planus
  • Lichen Sclerosus